DK1565467T3 - Hidtil ukendte vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse - Google Patents

Hidtil ukendte vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse

Info

Publication number
DK1565467T3
DK1565467T3 DK03799611T DK03799611T DK1565467T3 DK 1565467 T3 DK1565467 T3 DK 1565467T3 DK 03799611 T DK03799611 T DK 03799611T DK 03799611 T DK03799611 T DK 03799611T DK 1565467 T3 DK1565467 T3 DK 1565467T3
Authority
DK
Denmark
Prior art keywords
medicines
preparation
methods
pharmaceutical compositions
compositions containing
Prior art date
Application number
DK03799611T
Other languages
English (en)
Inventor
Jean-Marie Ruxer
Jean-Michel Lefrancois
Bertrand Heckmann
Original Assignee
Galapagos Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Sas filed Critical Galapagos Sas
Application granted granted Critical
Publication of DK1565467T3 publication Critical patent/DK1565467T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03799611T 2002-11-19 2003-11-12 Hidtil ukendte vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse DK1565467T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0214429A FR2847254B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
PCT/FR2003/003349 WO2004048375A1 (fr) 2002-11-19 2003-11-12 Nouveaux derives antagonistes du recepteur de la vitronectine leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
DK1565467T3 true DK1565467T3 (da) 2009-09-14

Family

ID=32187700

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09003174.1T DK2070914T3 (da) 2002-11-19 2003-11-12 Nye vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse
DK03799611T DK1565467T3 (da) 2002-11-19 2003-11-12 Hidtil ukendte vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09003174.1T DK2070914T3 (da) 2002-11-19 2003-11-12 Nye vitronektinreceptor-antagonistderivater, fremgangsmåde til fremstilling heraf, anvendelse heraf som medikamenter og farmaceutiske sammensætninger indeholdende disse

Country Status (28)

Country Link
US (2) US7582640B2 (da)
EP (2) EP2070914B1 (da)
JP (1) JP4567459B2 (da)
KR (1) KR101140752B1 (da)
CN (2) CN101928287A (da)
AR (2) AR042068A1 (da)
AT (2) ATE431825T1 (da)
AU (2) AU2003299330B2 (da)
BR (1) BR0316307A (da)
CA (1) CA2506310C (da)
CO (1) CO5700761A2 (da)
CY (1) CY1112218T1 (da)
DE (1) DE60327712D1 (da)
DK (2) DK2070914T3 (da)
ES (2) ES2369561T3 (da)
FR (1) FR2847254B1 (da)
HK (2) HK1076277A1 (da)
IL (2) IL168136A (da)
MA (1) MA27492A1 (da)
MX (1) MXPA05005340A (da)
NO (1) NO20052491D0 (da)
PL (1) PL376866A1 (da)
PT (2) PT2070914E (da)
RU (1) RU2412185C2 (da)
SI (2) SI1565467T1 (da)
TW (1) TW200412969A (da)
WO (1) WO2004048375A1 (da)
ZA (1) ZA200502850B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
HUE051802T2 (hu) 2018-08-17 2021-03-29 Oxurion NV Integrin antagonisták
WO2021165206A1 (en) 2020-02-19 2021-08-26 Oxurion NV Treatment of dry amd with integrin antagonists
CA3183338A1 (en) 2020-06-29 2022-01-06 Thomas S. Ickovic Systems, methods, and program products for digital pet identification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
CA2190870A1 (en) 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
WO1996000730A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
CA2259224A1 (en) 1996-06-28 1998-01-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Phenylalamine derivatives as integrin inhibitors
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
SK10632000A3 (sk) 1998-01-23 2001-02-12 Aventis Pharma Deutschland Gmbh Sulfónamidové deriváty ako inhibítory resorpcie kostí a inhibítory bunkovej adhézie
EP1054871A2 (en) * 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
HUP0103090A3 (en) * 1998-08-07 2002-12-28 Smithkline Beecham Corp Vitronectin receptor antagonist oxazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
ATE248646T1 (de) * 1999-10-05 2003-09-15 Element Six Pty Ltd Wachstum von diamantclustern
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
IL205693A (en) 2011-06-30
JP2006508999A (ja) 2006-03-16
ES2325616T3 (es) 2009-09-10
CN1738817A (zh) 2006-02-22
AU2003299330B2 (en) 2009-09-17
NO20052491L (no) 2005-05-23
HK1129372A1 (en) 2009-11-27
CO5700761A2 (es) 2006-11-30
FR2847254A1 (fr) 2004-05-21
DE60327712D1 (de) 2009-07-02
MXPA05005340A (es) 2005-11-17
PT1565467E (pt) 2009-07-15
ZA200502850B (en) 2005-10-25
CN1738817B (zh) 2011-12-21
AU2009212779B2 (en) 2011-09-01
CA2506310A1 (fr) 2004-06-10
AU2009212779A1 (en) 2009-09-17
ATE431825T1 (de) 2009-06-15
EP1565467B1 (fr) 2009-05-20
HK1076277A1 (en) 2006-01-13
DK2070914T3 (da) 2011-11-21
RU2005119163A (ru) 2006-02-27
SI2070914T1 (sl) 2012-02-29
FR2847254B1 (fr) 2005-01-28
CN101928287A (zh) 2010-12-29
BR0316307A (pt) 2005-09-27
PL376866A1 (pl) 2006-01-09
ATE518842T1 (de) 2011-08-15
EP2070914B1 (fr) 2011-08-03
SI1565467T1 (sl) 2009-10-31
KR101140752B1 (ko) 2012-05-03
US20060052398A1 (en) 2006-03-09
RU2412185C2 (ru) 2011-02-20
AU2003299330A1 (en) 2004-06-18
PT2070914E (pt) 2011-10-12
CY1112218T1 (el) 2015-12-09
ES2369561T3 (es) 2011-12-01
NO20052491D0 (no) 2005-05-23
EP2070914A1 (fr) 2009-06-17
WO2004048375A1 (fr) 2004-06-10
US20090149476A1 (en) 2009-06-11
JP4567459B2 (ja) 2010-10-20
KR20050083926A (ko) 2005-08-26
AR042068A1 (es) 2005-06-08
TW200412969A (en) 2004-08-01
IL168136A (en) 2012-06-28
CA2506310C (fr) 2014-04-08
MA27492A1 (fr) 2005-08-01
US7763621B2 (en) 2010-07-27
AR077476A2 (es) 2011-08-31
EP1565467A1 (fr) 2005-08-24
US7582640B2 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
DK1720544T3 (da) Nye azabicykliske derivater, fremstillingsmetode hertil og farmaceutiske sammensætninger indeholdende disse
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20042805L (no) Nye forbindelser og deres anvendelse innen medisin, fremgangsmate for deres fremstilling og farmaoytiske sammensetninger som inneholder dem
DK1490062T3 (da) Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
DK1601363T3 (da) Anvendelse som lægemiddel af derivater af cholest-4-en-3-on, farmaceutiske sammensætninger indeholdende disse og nye derivater
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
DK1448195T3 (da) N-adamantylmethylderivater og mellemprodukter som farmaceutiske præparater og fremgangsmåde til fremstilling deraf
NO994620D0 (no) Nye 2-(iminometyl)amino-fenyl-derivater, fremstilling, anvendelse som medisiner og farmasöytiske blandinger inneholdende disse
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
DK1558612T3 (da) Imidazopyridinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
HK1129372A1 (en) New antagonist derivatives of the vitronectin receptor, method for their preparation, their application as medicine and pharmaceutical compositions containing them
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
DK1655030T3 (da) Benzothiadiazinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger, som indeholder disse
BRPI0312413A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
DK1696913T3 (da) Vinfluninholdigt farmaceutisk præparat til parenteral administration, fremgangsmåde til fremstilling deraf og dets anvendelse
NO20054495D0 (no) Nye anilinderivater, deres fremstilling og anvendelse som farmasoytiske forbindelser
ATE516011T1 (de) Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten
DK1241169T3 (da) Isoindoloindolonforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1215213T3 (da) Bicylliske aminopyrazinonderivater, fremstilling deraf og farmaceutiske sammensætninger, som indeholder disse
DK1277746T3 (da) Nye N-benzylpiperazinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse